Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group
Holzkirchen, February 10, 2016 - Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).
In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be:
- Increasing stakeholder awareness and understanding through education
- Strengthening regulatory and scientific concepts
- Advocating for industrial policies that supports growth of the biosimilars industry
“The EBG has made tremendous progress in strengthening the impact of biosimilars in Europe. As the newly elected Chair, I look forward to representing the EBG during what promises to be another important two years for all biosimilar stakeholders” said Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz.
About Carol Lynch
Lynch leads a 3000+ person organization focused on the development, manufacturing and commercialization of biosimilars and oncology injectables. She is also responsible for Sandoz’s biopharmaceutical contract manufacturing business. Lynch has more than 25 years of global pharmaceutical and generics industry experience. Prior to joining Sandoz in 2014, Lynch held several Commercial and Development leadership positions in Novartis Pharmaceuticals both globally and in country organizations, including the United States. She is a member of the Sandoz Executive Committee, and Chair of the European Biosimilars Group.
About the EBG
The European Biosimilars Group (EBG), a sector group of the EGA, represents the leading companies in the biosimilar medicines space. Sandoz and the other EBG Members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.